ESLAW — Estrella Immunopharma Inc.

Stock analysis, AI verdict, fundamentals & technical signals

Rating: NEUTRAL

Price: $0.07

About Estrella Immunopharma Inc.

Estrella Immunopharma, Inc., a preclinical-stage biopharmaceutical company, develops T-cell therapies for blood cancers and solid tumors in the United States. The company is headquartered in EmeryVille, California.

See the full interactive analysis & chart →

Informational only — not investment advice.